C4 Therapeutics (CCCC) Total Liabilities (2019 - 2026)

C4 Therapeutics' Total Liabilities history runs 8 years deep, the most recent figure standing at $94.6 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 23.93% year-over-year to $94.6 million; the TTM figure through Mar 2026 stood at $94.6 million (down 23.93% YoY), while the FY2025 annual figure was $102.5 million, down 23.3% from the prior year.
• Total Liabilities was $94.6 million for Q1 2026 at C4 Therapeutics, down from $102.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $151.0 million in Q1 2022 to a low of $94.6 million in Q1 2026.
• Historically, Total Liabilities has averaged $129.5 million across 5 years, with a median of $133.6 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Total Liabilities jumped 36.86% in 2022, then slipped 23.93% in 2026.
• A 5-year view of Total Liabilities shows it stood at $141.6 million in 2022, then retreated by 7.96% to $130.3 million in 2023, then advanced by 2.52% to $133.6 million in 2024, then retreated by 23.3% to $102.5 million in 2025, then dropped by 7.68% to $94.6 million in 2026.
• The last three Total Liabilities figures came in at $94.6 million (Q1 2026), $102.5 million (Q4 2025), and $111.1 million (Q3 2025), per Business Quant data.